Bristol-Myers passed on its $475M deal to option F-star drug; Zymeworks IPO raises $59M
→ A little more than two years ago, Bristol-Myers agreed to ante up $50 million to get an option on F-star’s experimental cancer drug for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
